Avey Leaves 23andMe to Start Alzheimer's Research Foundation Using DTC Genomics Firm's Platform
September 09, 2009
Avey Leaves 23andMe to Start Alzheimer's Research Foundation Using DTC Genomics Firm's Platform
The new Alzheimer's disease research foundation to be launched by Linda Avey will use 23andMe's research platform and its database of genetic risk association information to investigate the causes and discover new treatments for the disease.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Adding Alzheimer's Risk Option, 23andMe Revives Questions on Utility of DTC Genomics
April 20, 2011 / Pharmacogenomics Reporter - Rodent Study Suggests Low-Dose Pioglitazone May Improve Cognitive Function in Alzheimer's Patients
July 25, 2012 / Pharmacogenomics Reporter - Duke University Keeping an Eye on DTC Genomics Firms that Might be Infringing its APOE Patents
April 27, 2011 / Pharmacogenomics Reporter - Takeda to Use Zinfandel's TOMM40 Test in Alzheimer's Development Program for Actos
January 12, 2011 / Pharmacogenomics Reporter - DTC Genomics Gets Time Before FDA as Agency Considers Regulatory Strategy
July 21, 2010 / Pharmacogenomics Reporter